NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant...

13
NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care

Transcript of NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant...

Page 1: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Managing Solitary Brain Metastases from NSCLC

Dr Paula Mulvenna

Consultant Clinical Oncologist

Northern Centre for Cancer Care

Page 2: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

This Talk:• Prevalence of solitary brain metastases• Case histories

• Investigation – mandatory modalities• Patients suitable for aggressive (radical)

management

• Pathway• Summary

Page 3: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Incidence – a Global issue• 2002:

– 10.2 million new cancers worldwide

– 1.35 million lung cancers

• 2020– 15 million new cases

cancer– 2 million lung

• 50% of these will develop intracranial metastatic disease

• Parkin et al CA Cancer J Clin 2005

• Patients with brain metastases from lung cancer:– USA: ~85,000 patients per

annum– UK: ~40,000 patients per

annum

• 35% have solitary metastasis • 65% multiple metastases• Median survival < 6m

Page 4: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Incidence, a Local Issue: NCIN e-atlas

Page 5: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Stage

442%

2A0%

3A14%

3B32%

nk4%

2B1%

1B3%

1A4%

Crude Incidence, a Local Issue:NSCLC Referrals (to PMM) since 2001- 2008 (n=1810)

• Treatment Intent:– Palliative – 83%– Radical – 17%

• 10% presented with brain metastases

• 24% of those with stage III disease have then developed brain metastases (after combined modality treatment up front)

• i.e. in my day to day practice:

• 215 patients with NSCLC + Brain metastases between 2001-8– 1 per fortnight

Page 6: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Case History 1• 67 year old female – • non-smoker

• Cough Feb 2010• RUL adenocarcinoma• T2 N1M0

• Staging – aiming for radical surgical approach… until CT head…..

March 2010

Page 7: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Case History 1 cont’d• Chemotherapy (JG)• Radiological Almost CR• PS 0/1 (KPS 90)

• ?Role for radical management of intra and extra cranial Disease

• PET (renal CT) • MRI brain

Sept 2010Radical RT to RUL remnant Oct 2010

Gamma Knife SRS to brain met Nov 2010

Intra-thoracic Local recurrence March 2012 – brain clear

Further systemic treatment

Page 8: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Case History 2• 57 year old male• Feb 2011: Post chest

pain + haemoptysis• Life long smoker (50 pack

year)• Alcohol xs; Lives alone

• RUL squamous cell cancer 2010

• T3N2M0 (CT head clear)• PS 1 (but other tobacco

related co morbidities)

• Gem Carbo chemo

• Good PR

• Radical RT – • Good PR Aug 2011

Page 9: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Case History 2 cont’d

• Feb 2012 – unsteady, falls ++

• MRI brain – 5x4 cm right cerebellar cystic mass

• Extra cranial disease - active

Page 10: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Micro-Surgical resectionor Stereotactic Radiosurgery (SRS)?• For solitary metastasis – comparable outcomes

– Kalkanis et al J. Neuro Oncology 2010; 96(1): 33-43

• Surgical series: superficial, larger, midline shift– Best results if complete en bloc resection– Where possible, avoid piecemeal resection

Do less well if >9.5cm or if removed piecemeal

Page 11: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Micro-Surgical resectionor Stereotactic Radiosurgery (SRS)?

•SRS

•smaller (<3cm)

•Deep seated

•Less mid line shift

•Both (Sx or SRS) provide comparable local control and overall survival (ms >10m)

•Addition of WBRT – further intra cranial control; no further benefit seen in OS

Page 12: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Pathway• Patient Presents with possible solitary metastasis

from confirmed NSCLC– PS 0/1 (KPS 90 – 100)– MRI Head– Full Staging of extra-cranial Disease - PET-CT

• Lung MDT• Neuro-Oncology MDT (central)• Decision re microsurgical resection or SRS

• De novo presentation - ?surgery for thoracic component / non-surgical oncological radical approach

Page 13: NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

NECN Lung NSSG April 2012

Summary• Solitary metastasis

• Good PS (ECOG 0-1)

• No extra cranial metastatic disease

• Radically treatable primary